What To Expect From Haemonetics’s (HAE) Q2 Earnings
Haemonetics (NYSE: HAE) reports Q2 earnings Thursday before market open. The company last quarter reported revenue of $346.4M, up 4.8% YoY, beating revenue and narrowly beating EPS estimates. For Q2, analysts expect revenue up 2.7% YoY. HAE shares are up 13.8% over the past month; average analyst price target is $87.90 vs $85.38.
How this was made
The 30-second read
Why it matters
Traders can use the stated consensus revenue growth (2.7% YoY) and the note that Haemonetics rarely misses revenue estimates to calibrate whether the upcoming quarter is likely to be a beat or miss, and to position for pre-market volatility.
Market read
The article is primarily a setup for an earnings catalyst, highlighting consensus expectations and peer outcomes that may influence sentiment into the release.
What to watch
The preview emphasizes revenue growth and estimate stability but does not detail margins, cash flow, or guidance language that often drives the largest earnings reactions.
Background
Haemonetics is scheduled to report Q2 results this Thursday before market open; the article frames expectations using prior-quarter performance and recent peer prints.
Ticker impact
Haemonetics reports Q2 results this Thursday pre-market, with the article citing consensus revenue growth of 2.7% YoY and recent estimate reconfirmations.
Near-term volatility likely around the pre-market earnings release versus the cited revenue and EPS expectations.
The article provides timing (this Thursday before open) and quantified expectations (2.7% revenue growth YoY) but does not disclose any new company-specific guidance or datapoint beyond prior-quarter results.
Market effects
Peer results in medical devices specialty are used as a read-through, potentially influencing how traders frame demand trends for the segment.
No specific regional market linkage is provided.
No explicit global macro or cross-border catalyst is described.
Counterpoint
The peer read-through may not translate if Haemonetics faces idiosyncratic demand, pricing, or product-cycle timing that differs from Inspire and Integer.
Key entities
- companyHaemonetics
Blood products company scheduled to report Q2 results this Thursday before market open.
- companyInspire Medical Systems
Peer cited as having reported Q2 revenue down 7.6% YoY but beating expectations, with shares up 22.6% after results.
- companyInteger Holdings
Peer cited as having reported Q2 revenue down 2.6% YoY but topping estimates, with shares up 3.2%.
